GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (NAS:OPGN) » Definitions » Net-Net Working Capital

OpGen (OPGN) Net-Net Working Capital : $-1.42 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OpGen Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

OpGen's Net-Net Working Capital for the quarter that ended in Sep. 2023 was $-1.42.

The industry rank for OpGen's Net-Net Working Capital or its related term are showing as below:

OPGN's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.575
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

OpGen Net-Net Working Capital Historical Data

The historical data trend for OpGen's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Net-Net Working Capital Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.95 -9.88 -11.14 3.07 -3.36

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.25 -3.36 -1.64 -1.58 -1.42

Competitive Comparison of OpGen's Net-Net Working Capital

For the Medical Devices subindustry, OpGen's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OpGen's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where OpGen's Price-to-Net-Net-Working-Capital falls into.



OpGen Net-Net Working Capital Calculation

OpGen's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net-Net Working Capital(A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(7.44+0.75 * 0.514+0.5 * 1.345-18.238
-0-0)/2.89991
=-3.36

OpGen's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2023 is calculated as

Net-Net Working Capital(Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.293+0.75 * 0.423+0.5 * 1.198-15.458
-0-0)/10.0135
=-1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


OpGen  (NAS:OPGN) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


OpGen Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of OpGen's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


OpGen (OPGN) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Executives
Yvonne Schlaeppi director 600 EAST GREENWICH AVENUE, WEST WARWICK X1 02893
Johannes Bacher officer: Chief Operating Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Albert Weber officer: Chief Finanical Officer MARIENBURGER STR. 7, BERLIN 2M 10405
Oliver Schacht director, officer: Chief Executive Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Evan/ Fa Jones director, officer: Chief Executive Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
William E. Rhodes director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Curetis N.v. In Liquidation 10 percent owner MAX-EYTH-STRASSE 42, HOLZGERLINGEN 2M 71088
Mario Crovetto director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Vadim M. Sapiro officer: Chief Information Officer C/O OPGEN, INC,, 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Timothy C Dec officer: Chief Financial Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Jven Capital, Llc 10 percent owner P.O. BOX 60207, POTOMAC MD 20859
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Harry J D'andrea director 6480 DOBBIN ROAD, COLUMBIA MD 21045